Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer
Hashemi, Mehrdad (Islamic Azad University. Farhikhtegan Medical Convergence Sciences Research Center)
Esbati, Nastaran (Islamic Azad University. Farhikhtegan Medical Convergence Sciences Research Center)
Rashidi, Mohsen (Mazandaran University of Medical Sciences. Department Pharmacology)
Gholami, Sadaf (Islamic Azad University. Farhikhtegan Medical Convergence Sciences Research Center)
Raesi, Rasoul (Mashhad University of Medical Sciences. Department of Health Services Management)
Bidoki, Seyed Shahabadin (Shahid Sadoughi University of Medical Sciences)
Goharrizi, Mohammad Ali Sheikh Beig (University of Tehran)
Motlagh, Yasamin Sadat Mousavi (Shahid Sadoughi University of Medical Sciences)
Khorrami, Ramin (University of Tehran. Department of Food Hygiene and Quality Control)
Tavakolpournegari, Alireza (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Nabavi, Noushin (University of British Columbia. Department of Urologic Sciences and Vancouver Prostate Centre)
Zou, Rongjun (Guangzhou University of Chinese Medicine. Department of Cardiovascular Surgery)
Mohammadnahal, Leila (Islamic Azad University. Department of Health Services Management)
Entezari, Maliheh (Islamic Azad University. Farhikhtegan Medical Convergence Sciences Research Center)
Taheriazam, Afshin (Islamic Azad University. Department of Orthopedics)
Hushmandi, Kiavash (University of Tehran. Department of Food Hygiene and Quality Control)

Data:	2024
Resum:	The treatment of cancer patients has been mainly followed using chemotherapy and it is a gold standard in improving prognosis and survival rate of patients. Oxaliplatin (OXA) is a third-platinum anti-cancer agent that reduces DNA synthesis in cancer cells to interfere with their growth and cell cycle progression. In spite of promising results of using OXA in cancer chemotherapy, the process of drug resistance has made some challenges. OXA is commonly applied in treatment of colorectal cancer (CRC) as a malignancy of gastrointestinal tract and when CRC cells increase their proliferation and metastasis, they can obtain resistance to OXA chemotherapy. A number of molecular factors such as CHK2, SIRT1, c-Myc, LATS2 and FOXC1 have been considered as regulators of OXA response in CRC cells. The non-coding RNAs are able to function as master regulator of other molecular pathways in modulating OXA resistance. There is a close association between molecular mechanisms such as apoptosis, autophagy, glycolysis and EMT with OXA resistance, so that apoptosis inhibition, pro-survival autophagy induction and stimulation of EMT and glycolysis can induce OXA resistance in CRC cells. A number of anti-tumor compounds including astragaloside IV, resveratrol and nobiletin are able to enhance OXA sensitivity in CRC cells. Nanoparticles for increasing potential of OXA in CRC suppression and reversing OXA resistance have been employed in cancer chemotherapy. These subjects are covered in this review article to shed light on molecular factors resulting in OXA resistance.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Oxaliplatin ; Cancer chemotherapy ; Drug resistance ; Molecular pathways ; Colorectal cancer
Publicat a:	Translational Oncology, Vol. 40 (February 2024) , art. 101846, ISSN 1936-5233

DOI: 10.1016/j.tranon.2023.101846
PMID: 38042134

18 p, 15.6 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats